Hypertension is one of the most common causes of cardiovascular disease and death, being a major risk factor for stroke, coronary artery disease, chronic kidney disease and heart failure. Treatment-resistant hypertension is also a common occurrence, with an estimated 50 – 75% of patients being unable to reach blood pressure goals with drug monotherapy.
The large number of patients taking multiple drug therapy for hypertension and the considerable costs associated with these drugs are both factors which have led to the development of a number of combination antihypertensive products.
These combinations are promoted as having benefits such as increasing compliance and reducing costs, with patients only needing to pay for one co-payment if the product is listed on the Pharmaceutical Benefits Scheme (PBS) and having to take fewer tablets each day.
Read the complete bulletin:
The 2009 RGH E-Bulletins are archived here.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
A joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
Editor: Assoc. Prof. Chris Alderman, University of South Australia – Director of Pharmacy, RGH © Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia 5041.